Stock INTS INTENSITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
4 USD +6.38% Intraday chart for Intensity Therapeutics, Inc. +3.63% -53.33%
05-10 Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial MT
04-19 Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors CI

Valuation

Fiscal Period: December 2023 2024
Capitalization 1 117.5 54.84
Enterprise Value (EV) 1 117.5 54.84
P/E ratio -6.21 x -4.35 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA - -
EV / FCF - -
FCF Yield - -
Price to Book - -
Nbr of stocks (in thousands) 13,709 13,709
Reference price 2 8.570 4.000
Announcement Date 24-03-14 -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024
Net sales 1 - - -
EBITDA - - -
EBIT 1 - -8.319 -10.1
Operating Margin - - -
Earnings before Tax (EBT) 1 - -10.54 -9.35
Net income 1 -7.582 -11.86 -9.35
Net margin - - -
EPS 2 -2.220 -1.380 -0.9200
Free Cash Flow - - -
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 23-05-18 24-03-14 -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - -
EBITDA - - - - - - -
EBIT -1.222 -2.491 -3.353 - - - -
Operating Margin - - - - - - -
Earnings before Tax (EBT) -3.701 -2.33 -3.171 - - - -
Net income -3.701 -2.33 -4.495 - - - -
Net margin - - - - - - -
EPS 2 -1.050 -0.1700 -0.1200 -0.3400 - - -
Dividend per Share - - - - - - -
Announcement Date 23-08-14 23-11-13 24-03-14 24-05-09 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024
Net Debt - - -
Net Cash position - - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow - - -
ROE (net income / shareholders' equity) - - -
ROA (Net income/ Total Assets) - - -
Assets 1 - - -
Book Value Per Share - - -
Cash Flow per Share 2 - -0.8400 -0.5300
Capex - - -
Capex / Sales - - -
Announcement Date 23-05-18 24-03-14 -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4 USD
Average target price
12 USD
Spread / Average Target
+200.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INTENSITY THERAPEUTICS, INC. Stock Intensity Therapeutics, Inc.
-53.33% 54.84M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INTS Stock
  4. Financials Intensity Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW